Effect of a matrix metalloproteinase activity and TNF-alpha converting enzyme inhibitor on intra-abdominal adhesions

European Surgical Research

Volumn 37, Issue 1, 2005, Pages 68-75

  Mirastschijski, U ^a   Johannesson, K ^a   Jeppsson, B ^a   Agren M S ^b,c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Bromodeoxyuridine; Collagen; Galardin; GM 6001; Hydroxamate inhibitor; Ilomastat; Peritoneum; Wound healing

Indexed keywords

HYDROXYPROLINE; ILOMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; NONHUMAN; PATHOGENESIS; PERITONEUM ADHESION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; TISSUE LEVEL; WOUND HEALING;

ADAM PROTEINS; ADHESIONS; ANIMALS; CELL DIVISION; DIPEPTIDES; FEMALE; HYDROXYPROLINE; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; PERITONEAL DISEASES; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 17844400983     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083150     Document Type: Conference Paper

References (41)

1. Holmdahl L: Making and covering of surgical footprints. Lancet 1999;353:1456-1457.
2. Parker MC, Ellis H, Moran BJ, Thompson JN, Wilson MS, Menzies D, McGuire A, Lower AM, Hawthorn RJ, O'Briena F, Buchan S, Crowe AM: Postoperative adhesions: Ten-year follow-up of 12,584 patients undergoing lower abdominal surgery. Dis Colon Rectum 2001;44:822-830.
3. Cheong YC, Laird SM, Li TC, Shelton JB, Ledger WL, Cooke ID: Peritoneal healing and adhesion formation/reformation. Hum Reprod Update 2001;7:556-566.
4. Chegini N: Peritoneal molecular environment, adhesion formation and clinical implication. Front Biosci 2002;7:e91-e115.
5. Hellebrekers BW, Trimbos-Kemper TC, Trimbos JB, Emeis JJ, Kooistra T: Use of fibrinolytic agents in the prevention of postoperative adhesion formation. Fertil Steril 2000;74:203-212.
6. Molinas CR, Elkelani O, Campo R, Luttun A, Carmeliet P, Koninckx PR: Role of the plasminogen system in basal adhesion formation and carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice. Fertil Steril 2003;80:184-192.
7. Lai HS, Chen Y, Chang KJ, Chen WJ: Effects of octreotide on epidermal growth factor receptor, tissue plasminogen activator, and plasminogen activator inhibitor during intraperitoneal adhesion formation. J Gastroenterol 2003;38:555-560.
8. Imai A, Sugiyama M, Furui T, Takahashi S, Tamaya T: Gonadotrophin- releasing hormones agonist therapy increases peritoneal fibrinolytic activity and prevents adhesion formation after myomectomy. J Obstet Gynaecol 2003;23:660-663.
9. Ivarsson ML, Bergström M, Eriksson E, Risberg B, Holmdahl L: Tissue markers as predictors of postoperative adhesions. Br J Surg 1998;85:1549-1554.
10. Ince A, Eroglu A, Tarhan O, Bulbul M: Peritoneal fibrinolytic activity in peritonitis. Am J Surg 2002;183:67-69.
11. Lund LR, Rømer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, Stephens RW, Danø K: Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 1999;18:4645-4656.
12. Stamenkovic I: Extracellular matrix remodelling: The role of matrix metalloproteinases. J Pathol 2003;200:448-464.
13. Chegini N, Kotseos K, Zhao Y, Ma C, McLean F, Diamond MP, Holmdahl L, Burns J: Expression of matrix metalloproteinase (MMP-1) and tissue inhibitor of MMP in serosal tissue of intraperitoneal organs and adhesions. Fertil Steril 2001;76:1212-1219.
14. Chegini N, Zhao Y, Kotseos K, Ma C, Bennett B, Diamond MP, Holmdahl L, Skinner K: Differential expression of matrix metalloproteinase and tissue inhibitor of MMP in serosal tissue of intraperitoneal organs and adhesions. BJOG 2002;109:1041-1049.
15. Cheong YC, Shelton JB, Laird SM, Li TC, Ledger WL, Cooke ID: Peritoneal fluid concentrations of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and transforming growth factor-beta in women with pelvic adhesions. Fertil Steril 2003;79:1168-1175.
16. Kaidi AA, Gurchumelidze T, Nazzal M, Figert P, Vanterpool C, Silva Y: Tumor necrosis factor-alpha: A marker for peritoneal adhesion formation. J Surg Res 1995;58:516-518.
17. Zhu Z, Yao J, Wang F, Xu Q: TNF-alpha and the phenotypic transformation of human peritoneal mesothelial cell. Chin Med J (Engl) 2002;115:513-517.
18. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-733.
19. Trifilieff A, Walker C, Keller T, Kottirsch G, Neumann U: Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation. Br J Pharmacol 2002;135:1655-1664.
20. Galardy RE, Cassabonne ME, Giese C, Gilbert JH, Lapierre F, Lopez H, Schaefer ME, Stack R, Sullivan M, Summers B, Tressler R, Tyrrell D, Wee J, Allen SD, Castellot JJ, Barletta JP, Schultz GS, Fernandez LA, Fisher S, Cui TY, Foellmer HG, Grobelny D, Holleran WM: Low molecular weight inhibitors in corneal ulceration. Ann N Y Acad Sci 1994;732:315-323.
21. Ågren MS, Jorgensen LN, Delaissé JM: Matrix metalloproteinases and colon anastomosis repair: A new indication for pharmacological inhibition? Mini Rev Med Chem 2004;4:769-778.
22. Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y: Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: An examination of the subsite pocket. J Med Chem 1998;41:1209-1217.
23. Bendeck MP, Irvin C, Reidy MA: Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996;78:38-43.
24. Syk I, Ågren MS, Adawi D, Jeppsson B: Inhibition of matrix metalloproteinases enhances breaking strength of colonic anastomoses in an experimental model. Br J Surg 2001;88:228-234.
25. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaissé JM: The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003;18:859-867.
26. Nahas K, Provost JP, Baneux PH, Rabemampianina Y: Effects of acute blood removal via the sublingual vein on haematological and clinical parameters in Sprague-Dawley rats. Lab Anim 2000;34:362-371.
27. Holmdahl L, Al-Jabreen M, Risberg B: Experimental models for quantitative studies on adhesion formation in rats and rabbits. Eur Surg Res 1994;26:248-256.
28. Mirastschijski U, Impola U, Karsdal MA, Saarialho-Kere U, Ågren MS: Matrix metalloproteinase inhibitor BB-3103 unlike the serine proteinase inhibitor aprotinin abrogates epidermal healing of human skin wounds ex vivo. J Invest Dermatol 2002;118:55-64.
29. Foley-Comer AJ, Herrick SE, Al-Mishlab T, Prele CM, Laurent GJ, Mutsaers SE: Evidence for incorporation of free-floating mesothelial cells as a mechanism of serosal healing. J Cell Sci 2002;115:1383-1389.
30. Bittinger F, Schepp C, Brochhausen C, Lehr HA, Otto M, Köhler H, Skarke C, Walgenbach S, Kirkpatrick CJ: Remodeling of peritoneal-like structures by mesothelial cells: Its role in peritoneal healing. J Surg Res 1999;82:28-33.
31. Mutsaers SE, Whitaker D, Papadimitriou JM: Mesothelial regeneration is not dependent on subserosal cells. J Pathol 2000;190:86-92.
32. Ellis H, Harrison W, Hugh TB: The Healing of peritoneum under normal and pathological conditions. Br J Surg 1965;52:471-476.
33. Raftery AT: Regeneration of parietal and visceral peritoneum: A light microscopic study. Br J Surg 1973;60:293-299.
34. Witte MB, Thornton FJ, Kiyama T, Efron DT, Schulz GS, Moldawer LL, Barbul A: Metalloproteinase inhibitors and wound healing: A novel enhancer of wound strength. Surgery 1998;124:464-470.
35. Mutsaers SE: The mesothelial cell. Int J Biochem Cell Biol 2004;36:9-16.
36. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Bröcker EB, Friedl P: Compensation mechanism in tumor cell migration: Mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003;160:267-277.
37. Wong TT, Mead AL, Khaw PT: Matrix metalloproteinase inhibition modulates postoperative scarring after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2003;44:1097-1103.
38. Xu X, Rivkind A, Pappo O, Pikarsky A, Levi-Schaffer F: Role of mast cells and myofibroblasts in human peritoneal adhesion formation. Ann Surg 2002;236:593-601.
39. Mazolewski PJ, Barber A, Williams S, Simoni J, Davis S, Shires GT: Attenuating tumor necrosis factor-alpha does not ameliorate other cytokine and peroxidase products during sepsis. Am J Surg 1999;178:556-559.
40. Ramesh G, Reeves WB: TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835-842.
41. Echtenacher B, Weigl K, Lehn N, Männel DN: Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect Immun 2001;69:3550-3555.